Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Non-Current Deferred Tax Liability (2021 - 2024)

Prime Medicine's Non-Current Deferred Tax Liability history spans 4 years, with the latest figure at $134000.0 for Q1 2024.

  • For Q1 2024, Non-Current Deferred Tax Liability rose 74.03% year-over-year to $134000.0; the TTM value through Mar 2024 reached $134000.0, up 74.03%, while the annual FY2022 figure was $8.7 million, 46.57% up from the prior year.
  • Non-Current Deferred Tax Liability reached $134000.0 in Q1 2024 per PRME's latest filing, up from $108000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $8.7 million in Q4 2022 to a low of $77000.0 in Q1 2023.
  • Average Non-Current Deferred Tax Liability over 4 years is $2.6 million, with a median of $307500.0 recorded in 2022.
  • Peak YoY movement for Non-Current Deferred Tax Liability: skyrocketed 46.57% in 2022, then soared 74.03% in 2024.
  • A 4-year view of Non-Current Deferred Tax Liability shows it stood at $6.0 million in 2021, then skyrocketed by 46.57% to $8.7 million in 2022, then plummeted by 98.77% to $108000.0 in 2023, then rose by 24.07% to $134000.0 in 2024.
  • Per Business Quant, the three most recent readings for PRME's Non-Current Deferred Tax Liability are $134000.0 (Q1 2024), $108000.0 (Q2 2023), and $77000.0 (Q1 2023).